Slideshows

In this slide show we highlight some of the top news on lung cancer in 2016, including an immunotherapy approval from the FDA, and studies on depression in lung cancer patients, serious side effects to watch for when using immunotherapies, and more.

This slide show highlights some of the top news of 2016 on hematologic malignancies, including FDA approvals for myeloma, lymphoma, and leukemia, and studies on transplantation, risk of recurrence in AML patients, and more.

This slideshow takes a look at some of the top kidney cancer news of 2016, including FDA approvals, survival disparities, surgical approaches, and more.

This slide show highlights some of the top prostate cancer news of 2016, including studies on aspirin use and cancer risk, the increased incidence of colorectal tumors in prostate cancer patients, hormone therapy and a link to depression, and more.

This slide show highlights some of the top breast cancer news of 2016, including a study looking at optimal margins in DCIS, a trial on biosimilars, a new FDA approval, and more.

Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 4 highlights a period of further regulation on the tobacco industry, the advent of e-cigarettes, and more.

We present a summer reading list of 15 must-reads that cover the history of genes and cancer, the link between so-called junk DNA and disease, uncertainty in medicine, and more.

Read compelling analyses of 5-year trends and projected changes in the oncology clinical drug pipeline, selected from the IMS Institute for Healthcare Informatics’ recent “Global Oncology Trend Report.”

Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 3 highlights a period of regulation and legislation against the tobacco industry, and litigation in the form of class action and state lawsuits.

This slide show highlights some of the top stories of the month, including the approval of a new agent for RCC, a study that found declines in prostate cancer deaths have mirrored the declines in smoking rates, and more.

In case you missed it, check out our March recap featuring some of the latest in clinical trial news, a new indication for Afinitor, how genetics affect prognosis, and more.

In this March 2016 news roundup we highlight two new FDA indications, chemotherapy’s long-term effect on fertility, the link between BMI and thyroid cancer, and more.

In this news roundup we highlight new FDA indications, the overuse of advanced imaging in breast cancer, MAPK inhibition in melanoma, and more.

This slide show includes some of the top highlights from the 2016 ASCO Cancer Survivorship Symposium, including studies on whether lymphoma survivors receive the recommended care, how personalization improved survivorship care plan adherence among breast cancer patients, and more.

This slide show includes highlights from the 2016 ASCO Gastrointestinal Cancers Symposium, including studies on pancreatic cancer patients treated at a high-volume center, Lutathera in patients with midgut neuroendocrine tumors, and more.

This slide show includes some of the top highlights from the 2016 ASCO Genitourinary Cancers Symposium, including studies on hypofractionation in low-risk prostate cancer, cabozantinib in advanced RCC, and more.

In this slide show we take a look back at the past year in cancer news and research, with some of our most read stories of 2015 including new immunotherapy approvals, a look at the overtreatment of DCIS, a study on fish oil and chemoresistance, and more.

This slide show highlights the 2015 FDA approvals of cancer treatments, which included therapies for melanoma, RCC, sarcoma, and lung, breast, and pancreatic cancers, as well as various hematologic malignancies.